Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-term Follow-up of ND4 LHON Subjects Treated With GS010 Ocular Gene Therapy in the RESCUE or REVERSE Phase III Clinical Trials (RESTORE)

NCT03406104 is registered in ClinicalTrials.gov with GenSight Biologics as lead sponsor.

NCT NCT03406104
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03406104 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-term Follow-up of ND4 LHON Subjects Treated With GS010 Ocular Gene Therapy in the RESCUE or REVERSE Phase III Clinical Trials (RESTORE)
Lead sponsor
GenSight Biologics
Phase
Phase 3
Overall status
Completed
Start date
January 9, 2018
Completion date
July 4, 2022
Enrollment
62 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

leber hereditary optic neuropathy